GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

The Wednesday approval of the GSK vaccine, known in development as RSVPreF3 OA, covers the prevention of RSV infection in adults age 60 and older. GSK will market its new product under the brand ...

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease.

Preliminary data from GSK shows its RSV vaccine, Arexvy, could help protect people ages 50 to 59 against the virus. Leon Neal/Getty Images/FILE. CNN — ...

GSK expects to launch its respiratory syncytial virus (RSV) vaccine in the U.S. this year without supply constraints and sees China as a major future market for the shot, ...

New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.

The U.S. Food and Drug Administration on Friday approved GSK's respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the shot's accessibility to younger patients.

RSV kills more than 10,000 people ages 65 or older and around 300 children under 5 every year in the U.S. Cases spiked dramatically among infants this winter, which overwhelmed children’s ...